Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP
18/04/2026 06:04
April 18 (Reuters) - argenx SE ARGX.BR: ARGENX BRINGS NEUROMUSCULAR LEADERSHIP TO AAN 2026 WITH NEW DATA SUPPORTING BROADER VYVGART USE ACROSS MG AND CIDP ARGENX SE - PHASE 3 ADAPT OCULUS STUDY MET ITS PRIMARY ENDPOINT Source text: ID:nGNEccGTtJ Further company coverage: ARGX.BR ((Reuters.Briefs@thomsonreuters.com;))